Regenerative medicine is transforming how scientists approach chronic disease by shifting the focus from symptom management to biological repair. BioRestorative Therapies is developing stem cell–based therapies and biologic technologies aimed at addressing significant unmet needs across musculoskeletal and metabolic disorders.

Drug Development & Delivery recently interviewed Lance Alstodt, CEO of BioRestorative Therapies, about the development of its lead cell therapy candidate BRTX-100, the evolving regulatory and manufacturing landscape for autologous therapies, and how regenerative platforms could reshape treatment paradigms for chronic conditions.

Q. BioRestorative is positioned as a regenerative medicine company. Can you describe the company’s broader platform strategy and the key healthcare challenges you are aiming to address?

A: At BioRestorative, our focus is on developing biologically based solutions that address the underlying causes of chronic diseases rather than simply managing symptoms. Our pipeline spans both clinical-stage regenerative therapies and commercial biologic technologies, with programs targeting musculoskeletal degenerative disease, metabolic disorders, and regenerative aesthetics.

The foundation of our strategy is the use of advanced stem cell science and biologic signaling mechanisms to restore and repair damaged function. Through this platform approach, we are building multiple therapeutic and commercial opportunities that leverage our expertise in cell biology, manufacturing, and translational research.

Q. Your lead clinical program, BRTX-100, targets chronic lower back pain associated with degenerative disc disease. Why is this condition such a compelling target for regenerative therapies?

A: Chronic lower back pain affects more than 30 million adults in the United States and remains one of the most common causes of disability worldwide. Yet most existing treatment options, including pain medications, anti-inflammatory drugs, steroid injections, or surgery, primarily address symptoms rather than the underlying degeneration of the spinal disc.

Degenerative disc disease is fundamentally a biological problem involving deterioration of the disc structure and loss of functional cells, making it an ideal target for regenerative approaches designed to restore cellular function and repair damaged tissue, creating a healthy and sustainable disc environment.

Q. Chronic back pain is also closely tied to the opioid crisis. How do regenerative therapies potentially change the paradigm for pain management?

A: For many patients suffering from chronic back pain, the treatment pathway often involves long-term pain management strategies, including opioid-based medications. While these treatments can temporarily reduce pain, they do not address the underlying cause of the condition and can create additional risks for patients over time. Our team strives to change the approach from a transaction-based medicine system to a platform designed to address the generator of pain and truly heal the patient. Chronic pain afflicts so many; however, the opioid crisis is something we are very sensitive to, as more than 100k Americans each year die of opioid overdose. Our goal is to bring a solution that tackles the root of the problem.

Regenerative therapies offer a fundamentally different approach. By targeting the biological source of the pain, such as degeneration within the spinal disc, the goal is to restore function and reduce reliance on long-term pharmacologic pain management. If successful, therapies like BRTX-100 could represent a paradigm shift toward addressing both chronic pain and the broader societal challenges associated with opioid dependence.

Q. How does BRTX-100 work, and what makes it different from other treatment approaches currently available for chronic discogenic pain?

A: BRTX-100 is an autologous cell therapy derived from a patient’s own mesenchymal stem cells. These cells are harvested from bone marrow, expanded using proprietary techniques, and then injected directly into the damaged spinal disc in an outpatient procedure.

What makes the therapy particularly unique is the manufacturing process. The cells are expanded under low oxygen tension conditions, creating a strong, resilient cell, which helps prepare them to survive the toxic environment within the intervertebral disc. The goal is not simply to reduce pain but to restore biological function within the disc itself.

Q. BioRestorative recently completed enrollment in its Phase 2 trial for BRTX-100. What were the key milestones achieved, and what do they signal for the program’s development path?

A: The completion of enrollment in our prospective, randomized, double-blind, sham-controlled, single disc Phase 2 clinical trial represents a major milestone for the program. The study enrolled 99 patients across 15 clinical sites in the U.S., making it one of the largest and most rigorously designed FDA-authorized cell therapy trials conducted for chronic lumbar disc disease.

In parallel, we held a Type B meeting with the FDA through our Fast Track designation, which confirmed alignment on our proposed Phase 3 trial design, endpoints, and development assumptions. That level of regulatory alignment significantly reduces uncertainty as we prepare to advance toward late-stage clinical development. Now, our goal is to initiate Phase 3 activities and then secure approval of a commercial license, becoming the first company in the US to commercialize an autologous cell therapy for chronic lumbar degenerative disc disease.

Q. Manufacturing and scalability are often cited as key challenges for cell therapies. How is BioRestorative addressing those issues?

A: Manufacturing consistency and scalability are critical considerations for any cell therapy program. We are a vertically-integrated company and have oversight of the entire manufacturing process.

Our approach integrates proprietary cell expansion techniques with rigorous chemistry, manufacturing, and controls (CMC) frameworks designed to support late-stage clinical development and eventual commercialization.

Because BRTX-100 is an autologous therapy, each product is generated from the patient’s own cells. That requires highly controlled manufacturing processes that ensure reproducibility while maintaining the biological characteristics that make the therapy effective.

Q. Beyond the spine program, BioRestorative is also developing the ThermoStem® platform targeting metabolic disorders. What is the scientific premise behind this work?

A: ThermoStem® is a preclinical platform based on brown adipose–derived stem cells, which are associated with metabolically active brown adipose tissue. Unlike white fat, brown adipose tissue plays an important role in regulating energy expenditure and metabolic homeostasis.

By harnessing this biology, we believe it may be possible to develop novel therapies targeting conditions such as obesity and Type 2 diabetes. The platform also represents an opportunity to explore allogeneic, off-the-shelf stem cell approaches in metabolic disease.

Q. As regenerative medicine continues to evolve, what do you see as the most important developments shaping the future of cell-based therapies?

A: We are seeing a convergence of scientific, regulatory, and manufacturing advances that are enabling regenerative therapies to move from experimental concepts toward viable clinical solutions. Regulators are gaining greater familiarity with cell therapies, and clinical trial designs are becoming more rigorous and standardized.

At the same time, advances in cell processing, biologic characterization, and manufacturing infrastructure are improving the feasibility of bringing these therapies to patients. Together, these developments are helping regenerative medicine move closer to delivering meaningful new options for chronic diseases that currently have limited treatment pathways.